Roy Souradeep, Singh Sonam, Rawat Reema, Wadhwa Shikha, Munthala Dhanunjaya, Pojprapai Soodkhet, Mathur Ashish, Avasthi Devesh Kumar
Health Technology Cluster, School of Health Sciences and Technology, UPES (Bidholi), Dehradun, Uttarakhand 248007, India.
Department of Chemistry, School of Advanced Engineering, UPES (Bidholi), Dehradun, Uttarakhand 248007, India.
ACS Appl Bio Mater. 2025 Jan 20;8(1):715-725. doi: 10.1021/acsabm.4c01573. Epub 2025 Jan 7.
The Coronavirus Disease 2019 (COVID-19) recently emerged as a life-threatening global pandemic that has ravaged millions of lives. The affected patients are known to frequently register numerous comorbidities induced by COVID-19 such as diabetes, asthma, cardiac arrest, hypertension, and neurodegenerative diseases, to name a few. The expensiveness and probability of false negative results of conventional screening tests often delay timely diagnosis and treatment. In such cases, the deployment of a suitable biosensing platform can readily expedite the rapid diagnosis process for enhanced patient outcomes. We report the development of an electrochemical genosensor based on DNA/OGCN (DNA/oxygenated graphitic carbon nitride) nanohybrids for the quantification of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) DNA─the key biomarker for COVID-19. This is achieved by exploiting the molecular nanowire-formation capability of the [Ru(NH)] redox probe onto the DNA phosphate backbone via electrostatic interactions. The microstructural characterization of OGCN was performed using scanning electron microscopy (SEM) coupled with an energy-dispersive X-ray (EDX) module, X-ray diffraction (XRD), and Fourier transform infrared spectroscopy. The electrochemical analyses were performed using cyclic voltammetry (CV) and electrochemical impedance spectroscopy (EIS), while the analytical performance of the sensor was evaluated using square wave voltammetry (SWV). The developed sensor exhibited a wide linear detection range within 10 fM-10 μM, with a limit of detection (LoD) of ∼7.23 fM with a high degree of selectivity toward SARS-CoV-2 target DNA, thereby indicating its potential to be employed in a point-of-care scenario toward providing affordable healthcare to the global populace.
2019年冠状病毒病(COVID-19)最近成为一种危及生命的全球大流行病,已经夺走了数百万人的生命。已知受影响的患者经常出现由COVID-19引发的多种合并症,如糖尿病、哮喘、心脏骤停、高血压和神经退行性疾病等。传统筛查测试的昂贵性和假阴性结果的可能性常常延误及时诊断和治疗。在这种情况下,部署合适的生物传感平台可以迅速加快快速诊断过程,以改善患者的治疗效果。我们报告了一种基于DNA/OGCN(DNA/氧化石墨相氮化碳)纳米杂化物的电化学基因传感器的开发,用于定量严重急性呼吸综合征冠状病毒2(SARS-CoV-2)DNA——COVID-19的关键生物标志物。这是通过利用[Ru(NH)]氧化还原探针通过静电相互作用在DNA磷酸主链上形成分子纳米线的能力来实现的。使用扫描电子显微镜(SEM)结合能量色散X射线(EDX)模块、X射线衍射(XRD)和傅里叶变换红外光谱对OGCN进行微观结构表征。使用循环伏安法(CV)和电化学阻抗谱(EIS)进行电化学分析,同时使用方波伏安法(SWV)评估传感器的分析性能。所开发的传感器在10 fM-10 μM范围内表现出宽线性检测范围,检测限(LoD)约为7.23 fM,对SARS-CoV-2靶DNA具有高度选择性,从而表明其有潜力用于即时检测场景,为全球民众提供负担得起的医疗保健。